Announcements
Trials
Browse
Landscape
Eligibility
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoma, Mantle-Cell
×
Lenalidomide
×
Clear all
Filters
3
NCT01996865
2025-07-10
MAGNIFY
Celgene
Phase 3
Completed
503 enrolled
18 charts
1 FDA
NCT01021423
2019-11-19
RENEW
Celgene
Phase 3
Terminated
9 enrolled
10 charts